Publications
2022
Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms
Christian Pecquet,
Nicolas Papadopoulos,
Thomas Balligand,
Ilyas Chachoua,
Amandine Tisserand,
Gaëlle Vertenoeil,
Audrey Nédélec,
Didier Vertommen,
Anita Roy,
Caroline Marty,
Harini Nivarthi,
Jean-Philippe Defour,
Mira El-Khoury,
Eva Hug,
Andrea Majoros,
Erica Xu,
Oleh Zagrijtschuk,
Tudor E Fertig,
Daciana S Marta,
Heinz Gisslinger,
Bettina Gisslinger,
Martin Schalling,
Ilaria Casetti,
Elisa Rumi,
Daniela Pietra,
Chiara Cavalloni,
Luca Arcaini,
Mario Cazzola,
Norio Komatsu,
Yoshihiko Kihara,
Yoshitaka Sunami,
Yoko Edahiro,
Marito Araki,
Roman Lesyk,
Veronika Buxhofer-Ausch,
Sonja Heibl,
Florence Pasquier,
Violaine Havelange,
Isabelle Plo,
William Vainchenker,
Robert Kralovics,
Stefan N Constantinescu.
Blood. 2023 Feb 23;141(8):917-929. doi: 10.1182/blood.2022016846.
2022
Co-expression of mutated Jak2 and Calr enhances myeloproliferative phenotype in mice without loss of stem cell fitness
Christina M Schueller,
Andrea Majoros,
Harini Nivarthi,
Robert Kralovics.
Am J Hematol. 2022 Nov;97(11):E396-E399. doi: 10.1002/ajh.26688. Epub 2022 Aug 30.
2021
High-throughput drug screening identifies the ATR-CHK1 pathway as a therapeutic vulnerability of CALR mutated hematopoietic cells.
Jia R,
Kutzner L,
Koren A,
Runggatscher K,
Májek P,
Müller AC,
Schuster M,
Bock C,
Loizou JI,
Kubicek S,
Kralovics R.
Blood Cancer J. 2021 Jul 31;11(7):137. doi: 10.1038/s41408-021-00531-2.
2022
Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b
Jean-Jacques Kiladjian,
Christoph Klade,
Pencho Georgiev,
Dorota Krochmalczyk,
Liana Gercheva-Kyuchukova,
Miklos Egyed,
Petr Dulicek,
Arpad Illes,
Halyna Pylypenko,
Lylia Sivcheva,
Jiří Mayer,
Vera Yablokova,
Kurt Krejcy,
Victoria Empson,
Hans C Hasselbalch,
Robert Kralovics,
Heinz Gisslinger,
PROUD-PV Study Group.
Leukemia. 2022 May;36(5):1408-1411. doi: 10.1038/s41375-022-01528-x. Epub 2022 Feb 24.
2022
PD-L1 overexpression correlates with JAK2-V617F mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms
Jelena D Milosevic Feenstra,
Roland Jäger,
Fiorella Schischlik,
Daniel Ivanov,
Gregor Eisenwort,
Elisa Rumi,
Michael Schuster,
Bettina Gisslinger,
Sigrid Machherndl-Spandl,
Peter Bettelheim,
Maria-Theresa Krauth,
Felix Keil,
Christoph Bock,
Mario Cazzola,
Heinz Gisslinger,
Robert Kralovics,
Peter Valent.
Am J Hematol. 2022 Apr;97(4):390-400. doi: 10.1002/ajh.26461. Epub 2022 Jan 21.
2020
Myelomonocytic Skewing In Vitro Discriminates Subgroups of Patients with Myelofibrosis with A Different Phenotype, A Different Mutational Profile and Different Prognosis.
Geissler K,
Gisslinger B,
Jäger E,
Jäger R,
Schiefer AI,
Bogner E,
Fuchs E,
Schischlik F,
Alpar D,
Simonitsch-Klupp I,
Kralovics R,
Gisslinger H.
Cancers (Basel). 2020 Aug 14;12(8):2291. doi: 10.3390/cancers12082291.
2020
Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups.
Gisslinger H,
Klade C,
Georgiev P,
Krochmalczyk D,
Gercheva-Kyuchukova L,
Egyed M,
Rossiev V,
Dulicek P,
Illes A,
Pylypenko H,
Sivcheva L,
Mayer J,
Yablokova V,
Krejcy K,
Hasselbalch HC,
Kralovics R,
Kiladjian JJ.
Hemasphere. 2020 Oct 20;4(6):e485. doi: 10.1097/HS9.0000000000000485.
2020
5-Arylidene-2-(4-hydroxyphenyl)aminothiazol-4(5H)-ones with selective inhibitory activity against some leukemia cell lines.
Subtelna I,
Kryshchyshyn-Dylevych A,
Jia R,
Lelyukh M,
Ringler A,
Kubicek S,
Zagrijtschuk O,
Kralovics R,
Lesyk R.
Arch Pharm (Weinheim). 2021 Apr;354(4):e2000342. doi: 10.1002/ardp.202000342. Epub 2020 Nov 25.
2020
Multimodality imaging beyond CLEM: Showcases of combined in-vivo preclinical imaging and ex-vivo microscopy to detect murine mural vascular lesions.
Keuenhof K,
Heimel P,
Zopf LM,
Raigel M,
Turyanskaya A,
Kavirayani A,
Reier S,
Glösmann M,
Schöfer C,
Kralovics R,
Streli C,
Weninger WJ,
Geyer SH,
Slezak P,
Macfelda K,
Jäger R,
Wanek T,
Walter A.
Methods Cell Biol. 2021;162:389-415. doi: 10.1016/bs.mcb.2020.10.002. Epub 2020 Dec 2.
2021
5-Arylidene-2-(4-hydroxyphenyl)aminothiazol-4(5H)-ones with selective inhibitory activity against some leukemia cell lines.
Subtelna I,
Kryshchyshyn-Dylevych A,
Jia R,
Lelyukh M,
Ringler A,
Kubicek S,
Zagrijtschuk O,
Kralovics R,
Lesyk R.
Arch Pharm (Weinheim). 2021 Apr;354(4):e2000342. doi: 10.1002/ardp.202000342. Epub 2020 Nov 25.
